Navigating and championing early phase clinical trials

Phase I and Ib trials represent the first practical tests of your compound’s clinical relevance and commercial viability. They set the stage for subsequent studies that will ultimately determine your compound’s efficacy, safety and positive impact on patients’ lives.

Trialmed knows how to maximize success in early-phase development by anticipating potential challenges, recruiting the right patients, engaging top investigators and designing a trial that builds a platform for later-stage success. Our site-specific capabilities address all phases of clinical research, including first-in-human and early-phase studies. The anchor of our early phase capabilities is our Austin, Texas site, one of the largest and best-equipped early phase units globally, with a three-decade track record of delivering high-quality data, with a laser focus on patient safety and comfort.

Trialmed performs a critical assessment of your compound’s unique attributes to identify areas of strength and potential weakness that could impact the outcome of your current and subsequent trials. The team develops an integrated, early-phase program that leverages our facilities, site network, operational expertise and development experience to execute your trial in patients and/or healthy volunteers. Each step of the process is conducted with an eye toward supporting later-phase programs and regulatory submissions.

The partner you select for your early phase studies is critical in helping you achieve your overall development timeline efficiently and within budget. Our established network of carefully selected sites is centered around quality, medical safety and unparalleled expertise. Each of our global facilities undergo a rigorous selection process including GCP audits and/or pre-selection assessment visits. We also support a variety of indications and specialty populations through our global site network. Learn more about our specialist areas.